Ischemic stroke was the predominant subtype in these outcome trials, and SGLT2 inhibitors overall reduce new onset atrial fibrillation or flutter (AF/AFL)37, a major risk factor for ischemic stroke. Here, SLC5A2 is linked to atrial fibrillation.